Profile picture

Mrs Ana Calejo

Serca Pharmaceuticals, Oslo (Norway)
Membership: ESC Professional Member
Follow
Logo ESC

Contributor content

Novel first-in-class drug candidate protects from ischemia-reperfusion injury by targeting the SERCA2 complex
Presentation
Novel first-in-class drug candidate protects from ischemia-reperfusion injury by targeting the SERCA2 complex
Read more
New therapeutic strategy targeting regulation of the SERCA2 complex protects from myocardial ischemia-reperfusion injury
Presentation
New therapeutic strategy targeting regulation of the SERCA2 complex protects from myocardial ischemia-reperfusion injury
Read more
A novel drug candidate targeting the adrenergic regulation of the SERCA2 complex protect the heart from myocardial infarct injury
Presentation
A novel drug candidate targeting the adrenergic regulation of the SERCA2 complex protect the heart from myocardial infarct injury
Read more

ESC 365 is supported by

novartis Explore sponsored resources